(“Debiopharm”) announced a strategic partnership. Under the terms of the agreement, Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm’s pipeline. Both parties have furthermore agreed on a framework partnership pertaining to future clinical studies to be conducted by INC Research for Debiopharm.
“Debiopharm’s reputation in establishing partnerships is aligned very closely with our vision of creating strategic relationships that improve the speed, efficiency, and quality of drug development,” said Kelvin Logan, PhD., president INC Research Europe and Asia Pacific. “We are pleased to offer our therapeutic expertise along with our experience in conducting trials globally to support Debiopharm’s drug development efforts in bringing innovative medicines to market more quickly and efficiently.”
INC Research's clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer. The company's proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process® provides the foundation for successful strategic alliances.